ImmunityBio Inc (IBRX)

(19% Negative) ImmunityBio Inc (IBRX) Announces Delay in million Trials for situ (NMIBC CIS) Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Register to leave comments

  • News bot Jan. 29, 2026, 6:49 p.m.

    📋 ImmunityBio Inc (IBRX) - Clinical Trial Update

    Filing Date: 2026-01-15

    Accepted: 2026-01-15 08:35:47

    Event Type: Clinical Trial Update

    Event Details:

    ImmunityBio Inc (IBRX) Announces Clinical Trial Update ImmunityBio Inc (IBRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: million, approvals
    • Diseases/Conditions: situ (NMIBC CIS), first-line
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: NMIBC
    • Updated Timeline: December 31, 2024, December 31, 2025
      • anticipated in the first half of 2026

    🔬 Clinical Development Pipeline (ImmunityBio Inc):

    Product Type Development Stage Therapeutic Area Source
    Anktiva DRUG Phase PHASE2 Long COVID ClinicalTrials.gov
    Tumor Biopsy PROCEDURE Phase PHASE1 Metastatic Urothelial Carcinoma ClinicalTrials.gov
    Radiographic Imaging PROCEDURE Phase PHASE1 Metastatic Urothelial Carcinoma ClinicalTrials.gov
    Research Biospecimen Collection PROCEDURE Phase PHASE1 Metastatic Urothelial Carcinoma ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE1 Metastatic Urothelial Carcinoma ClinicalTrials.gov
    Enfortumab Vedotin (EV) DRUG Phase PHASE1 Metastatic Urothelial Carcinoma ClinicalTrials.gov
    Nogapendekin Alfa Inbakicept (N803) DRUG Phase PHASE1 Metastatic Urothelial Carcinoma ClinicalTrials.gov
    N803 DRUG Phase PHASE1 B-cell Non Hodgkin Lymphoma ClinicalTrials.gov
    Nogapendekin alfa inbakicept DRUG Phase PHASE2 Non-small Cell Lung Cancer Stage IV ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE2 Non-small Cell Lung Cancer Stage IV ClinicalTrials.gov
    Ipilimumab DRUG Phase PHASE2 Non-small Cell Lung Cancer Stage IV ClinicalTrials.gov
    rMBCG BIOLOGICAL Preclinical NMIBC ClinicalTrials.gov
    N-803 + Docetaxel + Nivolumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Docetaxel + Pembrolizumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Durvalumab + PD-L1 t-haNK DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Avelumab + PD-L1 t-haNK DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Atezolizumab + PD-L1 t-haNK DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Nivolumab + PD-L1 t-haNK DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Pembrolizumab + PD-L1 t-haNK DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Durvalumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Avelumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Atezolizumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Nivolumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Pembrolizumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Leukapheresis PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    ALT-803 DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    CIML NK cell infusion PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    G-CSF DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Mycophenolate mofetil DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Tacrolimus DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Graft cell infusion PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Irinotecan liposome DRUG Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    SBRT PROCEDURE Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    Leucovorin DRUG Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    5-Fluorouracil DRUG Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    Gemcitabine DRUG Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    Nab-paclitaxel DRUG Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    PD-L1 t-haNK BIOLOGICAL Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    Aldoxorubicin HCl DRUG Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    N-803 BIOLOGICAL Phase PHASE2 Pancreatic Cancer ClinicalTrials.gov
    Apheresis collection of MNCs (part A) OTHER Phase PHASE1 Metastatic Solid Tumor ClinicalTrials.gov
    N-803 (Cohort 2 part B) BIOLOGICAL Phase PHASE1 Metastatic Solid Tumor ClinicalTrials.gov
    M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B) BIOLOGICAL Phase PHASE1 Metastatic Solid Tumor ClinicalTrials.gov
    HCW9218 DRUG Phase PHASE1 Advanced Pancreatic Carcinoma ClinicalTrials.gov
    Tumor Treating Fields (TTFields, 200 kHz) DEVICE Phase PHASE2 Glioblastoma ClinicalTrials.gov
    Bevacizumab DRUG Phase PHASE2 Glioblastoma ClinicalTrials.gov
    N-803 (IL-15 Superagonist) DRUG Phase PHASE2 Long COVID ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE3 NSCLC Stage IV ClinicalTrials.gov
    Tislelizumab DRUG Phase PHASE3 NSCLC Stage IV ClinicalTrials.gov
    IBRX-042 DRUG Phase PHASE1 HPV-Related Carcinoma ClinicalTrials.gov
    M-CENK BIOLOGICAL Phase PHASE2 Platinum-resistant Ovarian Cancer ClinicalTrials.gov
    N-803 and Gemcitabine DRUG Phase PHASE2 Non-muscle Invasive Bladder Cancer (NMIBC) ClinicalTrials.gov
    N-803 and BCG DRUG Phase PHASE2 Non-muscle Invasive Bladder Cancer (NMIBC) ClinicalTrials.gov
    BCG( 50mg/Instillation) BIOLOGICAL Phase PHASE1 Non-muscle Invasive Bladder Cancer ClinicalTrials.gov
    BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) BIOLOGICAL Phase PHASE1 Non-muscle Invasive Bladder Cancer ClinicalTrials.gov
    NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Carboplatin and nab-paclitaxel plus atezolizumab. DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Carboplatin and paclitaxel plus atezolizumab and bevacizumab. DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Cisplatin/carboplatin and pemetrexed plus atezolizumab. DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Cisplatin/carboplatin and pemetrexed plus pembrolizumab. DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    NAI + Nivolumab + Ipilimumab DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    NAI + Pembrolizumab DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Rituximab DRUG Phase PHASE1 Non Hodgkin's Lymphoma Refractory/Relapsed ClinicalTrials.gov
    Fludarabine DRUG Phase PHASE1 Non Hodgkin's Lymphoma Refractory/Relapsed ClinicalTrials.gov
    CD19t-haNK suspension BIOLOGICAL Phase PHASE1 Non Hodgkin's Lymphoma Refractory/Relapsed ClinicalTrials.gov
    nogapendekin-alfa inbakicept DRUG Preclinical Lymphopenia ClinicalTrials.gov
    Daily oral dose of hepcortespenlisimut-L BIOLOGICAL Phase PHASE2 HCC ClinicalTrials.gov
    V-SARS BIOLOGICAL Phase PHASE1 Covid19 ClinicalTrials.gov
    Cetuximab DRUG Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    GI-6301 BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    GI-6207 BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    ETBX-061 BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    ETBX-051 BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    Aldoxorubicin hydrochloride BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    Sorafenib DRUG Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    Capecitabine DRUG Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    avelumab BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    haNK for infusion BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    GI-4000 BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    ETBX-011 BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma Non-resectable ClinicalTrials.gov
    aldoxorubicin DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    INNO-206 DRUG Phase PHASE1 Malignant Solid Tumour ClinicalTrials.gov
    Neukoplast™ (NK-92) BIOLOGICAL Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    hAd5-S-Fusion+N-ETSD vaccine BIOLOGICAL Phase PHASE1 COVID-19 ClinicalTrials.gov
    Topotecan DRUG Phase PHASE2 Metastatic Small Cell Lung Cancer ClinicalTrials.gov
    150 mg/m2 aldoxorubicin DRUG Phase PHASE2 Kaposi's Sarcoma ClinicalTrials.gov
    100 mg/m2 aldoxorubicin DRUG Phase PHASE2 Kaposi's Sarcoma ClinicalTrials.gov
    50 mg/m2 aldoxorubicin DRUG Phase PHASE2 Kaposi's Sarcoma ClinicalTrials.gov
    Bone marrow for correlative studies PROCEDURE Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    Peripheral blood for correlative studies PROCEDURE Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    IL-2 BIOLOGICAL Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    Cytokine-induced killer cells BIOLOGICAL Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    aNK for Infusion BIOLOGICAL Phase PHASE1 Pancreatic Cancer ClinicalTrials.gov
    Oxaliplatin DRUG Phase PHASE1 Pancreatic Cancer ClinicalTrials.gov
    Placebo (0.9% (w/v) saline) BIOLOGICAL Phase PHASE2 COVID-19 ClinicalTrials.gov
    hAd5-S-Fusion+N-ETSD BIOLOGICAL Phase PHASE2 COVID-19 ClinicalTrials.gov
    lovaza DRUG Phase PHASE1 Pancreatic Cancer ClinicalTrials.gov
    Fluorouracil DRUG Phase PHASE1 Pancreatic Cancer ClinicalTrials.gov
    250 mg/m2 aldoxorubicin DRUG Phase PHASE1 Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma ClinicalTrials.gov
    170 mg/m2 aldoxorubicin DRUG Phase PHASE1 Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma ClinicalTrials.gov
    Placebo BIOLOGICAL Phase PHASE1 COVID ClinicalTrials.gov
    BM-Allo.MSC BIOLOGICAL Phase PHASE1 COVID ClinicalTrials.gov
    Cisplatin DRUG Phase PHASE1 Triple Negative Breast Cancer ClinicalTrials.gov
    aNK (NK-92) + N-803 BIOLOGICAL Phase PHASE2 Stage IIIB Merkel Cell Carcinoma ClinicalTrials.gov
    aNK (NK-92) BIOLOGICAL Phase PHASE2 Stage IIIB Merkel Cell Carcinoma ClinicalTrials.gov
    350 mg/m2 aldoxorubicin DRUG Phase PHASE2 Glioblastoma ClinicalTrials.gov
    Necitumumab DRUG Phase PHASE1 Squamous Cell Carcinoma ClinicalTrials.gov
    ETBX-021 BIOLOGICAL Phase PHASE1 Squamous Cell Carcinoma ClinicalTrials.gov
    Sacituzumab Govitecan-Hziy DRUG Phase PHASE1 Advanced Triple Negative Breast Cancer ClinicalTrials.gov
    Doxorubicin DRUG Phase PHASE2 Metastatic Soft Tissue Sarcoma ClinicalTrials.gov
    haNK™ BIOLOGICAL Phase PHASE2 Merkel Cell Carcinoma ClinicalTrials.gov
    Saline OTHER Phase PHASE1 COVID-19 ClinicalTrials.gov
    Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) DRUG Phase PHASE3 Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma ClinicalTrials.gov
    N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab DRUG Phase PHASE3 Non Small Cell Lung Cancer ClinicalTrials.gov
    Regorafenib DRUG Phase PHASE1 Colorectal Cancer Metastatic ClinicalTrials.gov
    haNK BIOLOGICAL Phase PHASE1 Colorectal Cancer Metastatic ClinicalTrials.gov
    Interleukin 2 DRUG Phase PHASE1 Platinum-resistant Ovarian Cancer ClinicalTrials.gov
    Cytokine-Induced Memory-like Natural Killer Cells BIOLOGICAL Phase PHASE1 Platinum-resistant Ovarian Cancer ClinicalTrials.gov
    Stereotactic Body Radiation Therapy RADIATION Phase PHASE1 Urothelial Carcinoma ClinicalTrials.gov
    fulvestrant DRUG Phase PHASE1 Urothelial Carcinoma ClinicalTrials.gov
    5Fluorouracil (5-FU) DRUG Phase PHASE1 Urothelial Carcinoma ClinicalTrials.gov
    10-1074 BIOLOGICAL Phase PHASE1 HIV Infection ClinicalTrials.gov
    VRC07-523LS BIOLOGICAL Phase PHASE1 HIV Infection ClinicalTrials.gov
    5-Fluorouracil (5-FU) DRUG Phase PHASE1 Head and Neck Squamous Cell Carcinoma ClinicalTrials.gov
    N803 plus Bacillus Calmette-Guerin (BCG) DRUG Preclinical Non Muscle Invasive Bladder Cancer ClinicalTrials.gov
    Post-radiation immunotherapy RADIATION Phase PHASE2 High-risk Prostate Cancer ClinicalTrials.gov
    Androgen Deprivation Therapy (ADT) RADIATION Phase PHASE2 High-risk Prostate Cancer ClinicalTrials.gov
    External Beam Radiation Therapy (EBRT) RADIATION Phase PHASE2 High-risk Prostate Cancer ClinicalTrials.gov
    M-CENK (Activated NK Cells) DRUG Phase PHASE2 High-risk Prostate Cancer ClinicalTrials.gov
    ETBX-071 (PSA-based Oncolytic Virus) DRUG Phase PHASE2 High-risk Prostate Cancer ClinicalTrials.gov
    hAd5-SFusion+ N-ETSD (Oral capsule) DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    hAd5-S-Fusion+N-ETSD (Suspension for injection) BIOLOGICAL Phase PHASE1 Covid19 ClinicalTrials.gov
    haNK™ for Infusion BIOLOGICAL Phase PHASE1 Solid Tumor ClinicalTrials.gov
    haNK® BIOLOGICAL Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    omega-3 acid ethyl esters DRUG Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    nab paclitaxel DRUG Phase PHASE1 Non-small Cell Lung Cancer ClinicalTrials.gov
    omega-3-acid ethyl esters DRUG Phase PHASE1 Merkel Cell Carcinoma ClinicalTrials.gov
    Doxorubicin HCL DRUG Phase PHASE2 Triple Negative Breast Cancer (TNBC) ClinicalTrials.gov
    CD19 t-haNK- IV Administration BIOLOGICAL Phase PHASE2 Relapsed B-Cell Non Hodgkin Lymphoma ClinicalTrials.gov
    Intravesical Recombinant Mycobacterium (rMBCG) BIOLOGICAL Phase PHASE1 NMIBC ClinicalTrials.gov
    CD19 t-haNK BIOLOGICAL Phase PHASE1 Diffuse Large B Cell Lymphoma ClinicalTrials.gov
    EUA or approved vaccine BIOLOGICAL Phase PHASE1 COVID-19 ClinicalTrials.gov
    AAHI-SC3 Vaccine BIOLOGICAL Phase PHASE1 COVID-19 ClinicalTrials.gov
    AAHI-SC2 Vaccine BIOLOGICAL Phase PHASE1 COVID-19 ClinicalTrials.gov
    ETBX-071 DRUG Phase PHASE2 High-risk Prostate Cancer ClinicalTrials.gov
    carboplatin DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    5Fluorouracil DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ImmunityBio Inc
    • Ticker Symbol: IBRX